Drug Profile
MOL 4249
Alternative Names: MOL-4249Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Moleculin; University of Texas M. D. Anderson Cancer Center
- Developer Moleculin; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Antipsoriatics; Small molecules
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cutaneous T-cell lymphoma; Plaque psoriasis
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-II for Plaque psoriasis in USA (Topical)
- 28 Sep 2021 Discontinued - Preclinical for Cutaneous T-cell lymphoma in USA (Topical)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cutaneous-T-cell-lymphoma in USA (Topical, Ointment)